Kura Oncology Inc [KURA] stock prices are up 2.24% to $6.38 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KURA shares have gain 10.00% over the last week, with a monthly amount glided 3.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kura Oncology Inc [NASDAQ: KURA] stock has seen the most recent analyst activity on February 06, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, UBS started tracking the stock with Buy rating on October 24, 2024, and set its price target to $27. On October 14, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $19 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $26 on December 22, 2023. BofA Securities initiated its recommendation with a Buy and recommended $31 as its price target on August 11, 2023. Scotiabank started tracking with a Sector Perform rating for this stock on July 27, 2023, and assigned it a price target of $10.50. In a note dated May 17, 2023, BTIG Research initiated an Buy rating and provided a target price of $31 on this stock.
The stock price of Kura Oncology Inc [KURA] has been fluctuating between $5.41 and $23.48 over the past year. Currently, Wall Street analysts expect the stock to reach $12.5 within the next 12 months. Kura Oncology Inc [NASDAQ: KURA] shares were valued at $6.38 at the most recent close of the market. An investor can expect a potential return of 95.92% based on the average KURA price forecast.
Analyzing the KURA fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -2.99%, Pretax Profit Margin comes in at -2.64%, and Net Profit Margin reading is -2.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.44 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Kura Oncology Inc [NASDAQ:KURA]’s Current Ratio is 8.07. As well, the Quick Ratio is 8.07, while the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 8.12, the price to book ratio is 1.41.
Transactions by insiders
Recent insider trading involved Bair Teresa Brophy, Chief Legal Officer, that happened on May 19 ’25 when 1559.0 shares were sold. Chief Operating Officer, FORD KATHLEEN completed a deal on May 19 ’25 to sell 1558.0 shares. Meanwhile, Officer FORD KATHLEEN bought 1558.0 shares on May 19 ’25.
